Given the significantly reduced rate of cancer in anti-TIF1γ positive DM patients that also have anti-Sp4 or anti-CCAR1 autoantibodies, it has been suggested these autoantibodies could prove highly useful biomarkers to refine cancer risk and the need for further investigation and screening in this high-risk population [8–10]. This evidence concerns the gene TRIM33 and cancer.